Your patient support program has a brand problem

Your drug is launching in six months. The brand team has been deep in it for two years: the name, the visual identity, the messaging platform, the regulatory review cycles. The product brand is tight. Then someone asks about the patient support program (PSP). 

A name gets chosen, usually quickly. Colors get pulled from the drug brand. A logo gets built. It ships. Nobody in that room thinks of what just happened as a brand decision. The PSP is a program. The drug is the brand. 

That distinction is worth questioning, because it’s costing more than most teams realize. 

The program is already doing brand work 

Every interaction a patient support program has with a patient or healthcare professional (HCP) creates an impression. The name on an enrollment form. The tone of the first outreach call. Whether the visual experience of the support portal feels connected to what they just saw on the drug’s website, or completely foreign. These impressions accumulate into a brand experience, whether or not anyone designed them intentionally. 

For patients starting a specialty medication, the PSP is often the first substantive touchpoint within the treatment ecosystem, before the first prescription is filled, sometimes before the patient has even had time to process the diagnosis. What they experience in that moment shapes whether they engage with the program at all. Research from BrightInsight and Claritas Rx found that only 62% of specialty prescriptions result in a paid fill. And engagement with the program shapes whether they stay on treatment. 

That’s brand work. The question is whether your team is doing it deliberately. 

Why it’s harder than building any other brand in your portfolio  

Here’s where it gets complicated, and why “just apply the drug brand to the PSP” consistently falls short.  

The drug brand operates within tight promotional and regulatory guardrails. The PSP does too, but the guardrails are different and a bit looser. On the surface, that sounds like freedom. In practice, most teams respond to that freedom by defaulting to the drug brand anyway, which creates a different problem: a support program that reads like a product promotion to patients who don’t feel confident and clear on what the next step should be.  

It gets more complicated when the PSP serves more than one drug, which is common. Building a PSP around a single drug brand limits scalability across the broader pipeline, reducing the ability to leverage existing infrastructure and brand equity. Over time, this can create fragmented, product-specific PSPs, operational inefficiencies, and dilution of portfolio-wide brand value.  

The PSP also communicates things the drug brand can’t, and shouldn’t, touch. Injection training. Specialty pharmacy logistics. Prior authorization paperwork. Affordability programs. Side effect questions. These are PSP conversations. They require a brand with enough of its own identity to carry that content credibly, separate from the clinical claims of the drug itself.  

Then there’s the architecture problem. A single PSP might support two or three drugs across a manufacturer’s portfolio, each with its own brand, its own patient population, its own clinical story. Add the manufacturer’s corporate brand and, in many cases, a hub partner operating in the background, and you have a crowded room. Getting the brand architecture wrong, meaning which name appears where, how the PSP relates visually and verbally to each drug, what’s shared and what’s distinct, creates confusion at exactly the moments when patients and HCPs need clarity most. 

The diverse audiences who interact with the PSP and specifically the patient mindset when they first encounter it makes the PSP have to work even harder. Oftentimes, these are not medications available at a local pharmacy. They’re treatments reached after a long road: failed prior therapies, difficult diagnoses, insurance battles, and real anxiety about what comes next.  

An AMA survey of 1,000 practicing physicians found that 78% reported prior authorization often or sometimes leads their patients to abandon a recommended course of treatment. For the patients who make it through, the anxiety doesn’t stop at the prescription. A patient calling an injection support line for the first time needs to feel like someone thought carefully about their experience. Clarity and warmth are not nice-to-haves in that moment. They’re what determines whether the patient stays on the line. 

HCPs need something almost opposite. They’ve prescribed a complicated, expensive drug, and the last thing they want is their office fielding calls about benefits verification or specialty pharmacy delays. The PSP brand needs to signal, quickly and credibly, that it has this handled. That it reduces their team’s workload, not adds to it. The same program serves two very different emotional registers. 

What it actually means to build this brand 

Building a PSP brand requires thinking through a set of challenges that don’t come up in typical brand work. These four areas are where most programs fall short. 

Start with architecture, not aesthetics 

Before anyone discusses names or color palettes, the team needs to understand how this PSP relates to each drug it serves, what audiences it’s reaching, and which of its functions are shared versus specific to a given medication. Architecture decisions made here determine whether the program feels like a coherent system or a collection of disconnected pieces. Getting them right early also makes every downstream partner, the agency, the hub provider, the specialty pharmacy, more effective. They have a clear brand framework to work within rather than guessing. 

Design for the patient’s emotional state at each moment  

Enrollment is different from injection training, which is different from a refill reminder, which is different from a call about a side effect. Each of those moments has a different emotional register, and a well-built PSP brand is flexible enough to show up appropriately across all of them. The tone that reassures an anxious first-time patient on day one is not the same tone that confirms a shipment three months in. 

Give HCPs their own coherent experience 

The touchpoints an HCP encounters — benefits verification portals, rep-facing materials, office staff communications — should feel like a system built for them, not a patient-facing program with their name swapped in. HCPs need to trust quickly that the PSP reduces friction rather than adding it. That trust is built through consistency: every time an HCP or their staff interacts with the program, they should get the same clear, efficient, confidence-building experience. 

Build in governance from the start 

A PSP brand touches many hands. Hub partners, specialty pharmacies, field teams, and call center staff all represent it in some form. Without clear brand governance, those representations drift. The program that feels coherent on day one of launch starts to fragment as more operators touch it. Governance doesn’t mean rigidity; it means giving every partner who represents the PSP a clear understanding of what the brand stands for and how it should show up, so the patient and HCP experience stays consistent regardless of which part of the system they’re touching. 

Done right, these four tactics compound. A clear architecture makes governance easier. A consistent experience builds trust with both patients and HCPs. And that trust is ultimately what makes the program work. 

Choosing the right partner 

Building a PSP brand is not a natural fit for the partners most teams already have. Advertising and marketing agencies are built around promotion. Their inclination is to drive awareness and preference for the drug, and that instinct shapes how they approach everything, including the PSP. They’re less likely to ask how a program serves patients who are still anxious about starting treatment, or how a single brand identity needs to stretch across multiple medications or indications without creating confusion. 

Hub providers understand PSP operations deeply, but operational expertise and brand strategy are different disciplines. A hub can tell you how the program runs. It can’t tell you how participants should experience the program, or how to build an identity that holds up across every audience and touchpoint. 

Brand experience agencies bring a different orientation. Their starting point is the full ecosystem of people the brand has to serve and the moments it has to show up in. That’s exactly the kind of thinking a PSP brand requires: not what do we want people to think about this program, but how do we build something that earns trust from a nervous patient on day one, a skeptical office manager on day thirty, and an asset designed to deliver upon business objectives. 

Start before it ships 

If your PSP already exists, it’s worth asking honestly: does it have a brand, or just a name applied to a collection of services? 

If you’re building a PSP, the decisions you make about brand architecture now will shape every patient and HCP interaction that follows. The goal of a patient support program is to help people start and stay on treatment. Across 64 studies, 66% of those measuring adherence outcomes reported significantly positive results when patients were enrolled in a PSP.  

A brand built to do that deliberately, across every audience and every moment of the journey, is what makes that possible at scale.